Abstract:High cancer heterogeneity and aggressiveness are major factors contributing to the poor prognosis of patients with advanced cancer1-5. Early detection of cancer can significantly improve the prognosis of patients with early-stage cancer after standard treatment. Although traditional cancer detection technologies, such as endoscopy for gastrointestinal cancer, mammography for breast cancer, HPV DNA detection for cervical cancer, and computed tomography and positron emission tomography-computed tomography, are effective, these largely non-invasive screening methods pose various challenges, including patient resistance due to discomfort during the procedures, high costs, and requirements for specialized equipment and experienced physicians. Consequently, conducting these procedures on a large scale is difficult. The emergence of circulating cell-free DNA (cfDNA), newly identified non-encapsulated DNA molecules, has revolutionized cancer early detection by offering a comprehensive genomic perspective. The abundant information contained in cfDNA includes mutations, copy number variations, gene fusions, DNA methylation, microbiome or virus-released nucleic acids, T cell receptor sequences, mitochondrial DNA abnormalities, fragment ratios, associated histone modifications, transcription start site (TSS) coverage, and promoter fragmentation entropy (PFE)6,7. (Figure 1). These innovative technologies have shown potential in accurate and practical approaches to large-scale cancer screening and preoperative evaluation. Although cfDNA-based technologies offer substantial promise for early cancer detection, they also have several limitations. For instance, clonal hematopoiesis leads to most cfDNA mutations, which can be confused with the mutations induced by the circulating tumor DNA, thereby affecting the accuracy of cancer diagnosis and the method's clinical utility. Additionally, mutated gene panels have low detection rates in patients with early-stage cancer8, and DNA methylation, although stable, cannot reflect cell-specific programs or molecular dynamics9. Moreover, the bisulfite processing of cfDNA results in degradation of at least 84%-96% of the DNA, thus leading to a loss of valuable information10. Consequently, samples of hundreds of nanograms (ng) of DNA (derived from 10 mL blood) are required to mitigate the effects of clonal hematopoiesis, rare counts in cfDNA mutations, and the substantial amount of degraded DNA in cfDNA methylation analyses. Although the limitations of some cfDNA-based technologies, including fragment ratio, associated histone modifications, TSS coverage, and PFE, are unclear, these signatures can be used to infer gene expression levels and chromatin accessibility status, thereby indicating the functional state of cancer cells, and providing comprehensive information on dynamic biological processes and heterogeneity during tumorigenesis, in contrast to approaches focusing on certain mutations and CpG islands. Hence, the enormous potential of these cfDNA-based technologies, including fragment ratio, associated histone modifications, TSS coverage, and PFE, warrant further in-depth exploration.

A finite difference scheme for a system of two conservation laws with artificial viscosity

392P Integrating Fragmentomic Features for Non-Invasive Early Detection of Colorectal Advanced Adenoma and Adenocarcinoma

Systematically Evaluating Cell‐Free DNA Fragmentation Patterns for Cancer Diagnosis and Enhanced Cancer Detection via Integrating Multiple Fragmentation Patterns

Challenges and Prospects of Cell-Free DNA in Precision Oncology

Abstract 4950: Applying fragmentomics profiles of plasma cell-free DNA for breast cancer detection

Ultra-short Cell-Free DNA Fragments Enhance Cancer Early Detection in a Multi-Analyte Blood Test Combining Mutation, Protein and Fragmentomics.

DNA methylation analysis explores the molecular basis of plasma cell-free DNA fragmentation

Plasma cell-free DNA as a sensitive biomarker for multi-cancer detection and immunotherapy outcomes prediction

Analysis of a Cell-Free DNA-based Cancer Screening Cohort Links Fragmentomic Profiles, Nuclease Levels, and Plasma DNA Concentrations

Cell‐free DNA‐associated Multi‐feature Applications in Cancer Diagnosis and Treatment

Perspective on New Cell-Free DNA Technologies for Early Cancer Detection.

Integration of Cell-Free DNA End Motifs and Fragment Lengths Can Identify Active Genes in Liquid Biopsies

Unraveling cfDNA Fragmentation Patterns: Linking Chromatin Architecture to Cancer Diagnostic Sensitivity

Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study

Aberrant Fragmentomic Features of Circulating Cell-Free Mitochondrial DNA As Novel Biomarkers for Multi-Cancer Detection

Abstract 2290: Integration of cell-free DNA end motifs and fragment lengths can improve identification of active genes in liquid biopsies

Multi-Dimensional Cell-free DNA Fragmentomic Assay for Detection of Early-Stage Lung Cancer

Cell-free DNA Fragmentomics Assay to Discriminate the Malignancy of Breast Nodules and Evaluate Treatment Response

Dissecting cell-free DNA fragmentation variation in tumors using cell line-derived xenograft mouse

Genome-wide cell-free DNA fragmentation in patients with cancer

Characteristics, origin, and potential for cancer diagnostics of ultrashort plasma cell-free DNA